You are about to leave this site and are being redirected to another site. Would you like to leave this site?

For oncology nurses treating with BAVENCIO® (avelumab)

The nurse portal is your access point for information and resources that can help you effectively care for patients throughout BAVENCIO treatment.

uc-handbook

UC Nurse Handbook

Provides information to help nurses set expectations and care for patients undergoing treatment with BAVENCIO.

SETTING PATIENT EXPECTATIONS

Providing your patients with a clear understanding of what to expect during BAVENCIO maintenance treatment and what to do in certain situations can help them be better prepared.

Before treatment, it may be helpful to discuss with your patients:

What BAVENCIO maintenance treatment is and how it can help

How they will receive BAVENCIO

The importance of reporting adverse reactions

Who to call if they experience signs or symptoms of adverse reactions

ADMINISTERING BAVENCIO IN YOUR PATIENTS

BAVENCIO is administered as an 800 mg IV infusion over 60 minutes every 2 weeks.

800 MG IV INFUSION 

OVER 60 MINUTES

EVERY 2 WEEKS

Other important information to know about administration

OPEN ALL

CLOSE ALL

  • Premedicate patients with an antihistamine and with acetaminophen prior to the first 4 infusions of BAVENCIO
  • Premedication should be administered for subsequent BAVENCIO doses based upon clinical judgment and presence/severity of prior infusion reactions

See more on dosage and administration

  • BAVENCIO can cause severe or life-threatening infusion-related reactions
  • Premedicate with antihistamine and acetaminophen prior to the first 4 infusions
  • Monitor patients for signs and symptoms of infusion-related reactions including:
    • pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria
MODIFY TREATMENT BASED ON SEVERITY
Grade 1-2 Grade 3-4
Interrupt or slow the rate of infusion Stop the infusion and permanently discontinue BAVENCIO
MODIFY TREATMENT BASED ON SEVERITY
Grade 1-2
Interrupt or slow the rate of infusion
Grade 3-4
Stop the infusion and permanently discontinue BAVENCIO

Learn more about managing infusion-related reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and at any time after starting treatment, or after discontinuation. 

Discuss the importance of reporting any signs or symptoms of immune-mediated adverse reactions as soon as they occur

Learn about dose modifications for immune-mediate adverse reactions

See the BAVENCIO warnings and precautions

DOWNLOADABLE RESOURCES

Other downloadable resources to assist you in your practice

uc-handbook

UC Nurse Handbook

Provides information to help nurses set expectations and care for patients undergoing treatment with BAVENCIO.

adverse-reaction-checklist

Adverse Reaction Checklist

Helps facilitate conversations between nurses and patients about adverse reactions.

product-info-sheet

Product Information Sheet

Read more about BAVENCIO, including distributors, storage and handling requirements, and contact information for Customer Service.

patient-brochure

UC Patient Brochure

Helps answer questions about treatment, describes how BAVENCIO works and provides important safety information.

wallet-card

Patient Wallet Card

Helps your patients communicate with healthcare providers about the medicines they are taking.

Study design

 

Efficacy